Key result
Endothelial progenitor cell modulation represents a potential therapeutic target for preventing or reversing end-organ complications in diabetes.
Endothelial progenitor cells are altered in diabetes and represent a potential therapeutic target for preventing or reversing diabetic cardiovascular and end-organ complications.
No takes yet. Share an insight, caveat, or question.
Should not change diabetes practice yet; leaves open EPC modulation as a target pending prospective trials.
Fadini et al. (2010) conducted a review in Diabetes mellitus. Endothelial progenitor cells (EPCs) modulation was evaluated. Endothelial progenitor cell modulation represents a potential therapeutic target for preventing or reversing end-organ complications in diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: